Mediplantex National Pharmaceutical JSC (HNX:MED)
Vietnam · Delayed Price · Currency is VND 18,400
0.00 (0.00%)
At close: May 13, 2026
HNX:MED Revenue
Mediplantex National Pharmaceutical JSC had revenue of 43.45B VND in the quarter ending June 30, 2026, a decrease of -50.00%. This brings the company's revenue in the last twelve months to 291.40B, down -19.16% year-over-year. In the year 2025, Mediplantex National Pharmaceutical JSC had annual revenue of 366.83B, down -17.22%.
Revenue (ttm)
291.40B
Revenue Growth
-19.16%
P/S Ratio
0.78
Revenue / Employee
940.00M
Employees
310
Market Cap
228.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 366.83B | -76.31B | -17.22% |
| Jan 1, 2025 | 443.14B | 40.39B | 10.03% |
| Jan 1, 2024 | 402.74B | 1.69B | 0.42% |
| Dec 31, 2022 | 401.05B | 57.10B | 16.60% |
| Dec 31, 2021 | 343.95B | -177.44B | -34.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vidipha Central Pharmaceutical JSC | 979.05B |
| Ben Tre Pharmaceutical JSC | 873.41B |
| Vimedimex Medi-Pharma JSC | 812.98B |
| Pharmedic Pharmaceutical Medicinal JSC | 546.31B |
| Central Pharmaceutical Joint Stock Company No3 | 515.53B |
| Lamdong Pharmaceutical JSC | 262.06B |
| SPM Corporation | 217.45B |
| Cai Lay Veterinary Pharmaceutical JSC | 153.97B |